Provided by Tiger Trade Technology Pte. Ltd.

LAEKNA-B

8.265
+1.85528.94%
Volume:7.60M
Turnover:58.19M
Market Cap:3.74B
PE:-14.01
High:8.265
Open:6.805
Low:6.805
Close:6.410
52wk High:19.360
52wk Low:5.370
Shares:452.00M
HK Float Shares:452.00M
Volume Ratio:7.04
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.590
ROE:-10.69%
ROA:-7.60%
PB:2.66
PE(LYR):-14.01
PS:12.43

Loading ...

Laekna-B (02105) Rises Over 21% in Early Trading as First Patient Enrolled in Phase I Trial of LAE118

Stock News
·
Yesterday

Laekna Reports 1H26 Turnaround on Licensing Income; Loss Narrows to RMB 2.55 Million

Bulletin Express
·
Sep 18

Laekna Issues 2.73 Million New Shares for RSU Vesting, Lifting Share Count by 0.61%

Bulletin Express
·
Sep 08

LAEKNA-B Issues 273,000 Shares to Settle RSU Vesting Under 2024 Equity Incentive Plan

Stock News
·
Sep 08

Laekna Files HKEX Next-Day Disclosure, Issues 2.73 Million New Shares to Lift Share Capital

Reuters
·
Sep 08

Laekna Maintains 449.33 Million Shares Outstanding in August 2026, Confirms Adequate Public Float

Bulletin Express
·
Sep 04

HK Stocks in Focus: LAEKNA-B (02105) Jumps Over 9% in Early Trading After First Patient Dosed in Phase I Trial

Stock News
·
Sep 01

LAEKNA-B Initiates First-Patient Dosing in Phase I Trial of LAE118, a Novel Pan-Mutant-Selective PI3Kα Inhibitor

Stock News
·
Sep 01

Laekna Enrolls First Patient in China Phase I Trial of Cancer Drug Candidate Lae118

Reuters
·
Sep 01

Analysts Just Made A Significant Upgrade To Their Laekna, Inc. (HKG:2105) Forecasts

Simply Wall St.
·
Aug 28

LAEKNA-B Announces Interim Results with Other Income Climbing 30.41% Year-on-Year

Deep News
·
Aug 26

LAEKNA-B (02105) Posts Interim Results: Other Income Up 30.41% to RMB 25.962 Million

Stock News
·
Aug 25

Laekna FY26 H1 Net Loss Narrows to RMB 2.55 Million; Revenue Rises to RMB 150.28 Million

Reuters
·
Aug 25

Laekna forecasts up to RMB155.00 million H1 2026 revenue, trims net loss by 96%

Bulletin Express
·
Aug 17

Laekna Expects H1 Net Loss no More than RMB 5 Million

Reuters
·
Aug 17

Laekna - Expects Revenue of Rmb145 Mln-Rmb155 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS
·
Aug 17

LAEKNA-B's LAE002 NDA Accepted by CDE, Signaling a Domestic AKT Inhibitor Major Launch

Stock News
·
Aug 13

Laekna Breast Cancer Drug NDA Accepted in China

MT Newswires Live
·
Aug 12

New Drug Application for Lae002 (Afuresertib) Accepted by China's National Medical Products Administration

THOMSON REUTERS
·
Aug 12

Laekna gains NMPA nod to review NDA for AKT inhibitor Afuresertib in HR+/HER2- breast cancer

Bulletin Express
·
Aug 12